Welcome to our dedicated page for Genetic Technologies Ltd. news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd. stock.
Genetic Technologies Ltd. (ASX: GTG, NASDAQ: GENE) is a pioneering molecular diagnostics company based in Australia, specializing in genetic testing and reproductive services. The company leverages an extensive array of international patents and allied research activities to explore the profound impact of DNA on health. Its operations span across the Asia Pacific region, offering specialized genetic tests that convert advanced health knowledge into practical applications for humans, animals, and plants.
One of the company's flagship products is BREVAGenplus, a clinically validated risk assessment test that helps in predicting the likelihood of non-hereditary breast cancer. This test has been a game changer in women's health, providing crucial insights that aid physicians in proactive health management. BREVAGenplus is primarily marketed to healthcare professionals, including breast healthcare and imaging centers, obstetricians/gynecologists (OBGYNs), and breast cancer risk assessment specialists.
Genetic Technologies Ltd. offers a broad spectrum of genetic testing services, encompassing medical, animal, forensic, and plant testing. The company's revenue is chiefly derived from markets in Australia and the United States. The organization operates through two primary segments: EasyDNA and GeneType/Corporate.
Recent developments underline the company’s ongoing commitment to innovation and expansion. For example, the company has recently reported the clinical adoption of its groundbreaking geneType Risk Assessment Tests across 12 states in the United States and at a national level in Australia. These tests are designed to provide a comprehensive risk assessment for various diseases, thereby enabling personalized healthcare.
Dr. Carolyn Young, a board-certified Obstetrician and Gynecologist based in Rockville, Maryland, has emphasized the significance of such tests. According to her, misconceptions about breast cancer risks—such as the belief that absence of family history equates to low risk—can be clarified through the use of geneType tests, which identify both hereditary and non-hereditary risks.
The company continues to make strides, as highlighted in their recent announcements. Genetic Technologies Ltd. aims to expand its market reach by launching new comprehensive tests and entering new global markets. These initiatives are part of the company’s strategic efforts to cement its position as a global leader in genomics-based tests in health, wellness, and serious disease.
For further information or inquiries, you can reach out to Simon Morriss, Chief Executive Officer, at investors@genetype.com.
Genetic Technologies (NASDAQ: GENE) has launched testing operations in the U.S. for its geneType genetic risk assessment product series. Utilizing the advanced facilities of Gene by Gene in Houston, the company aims to process up to 25,000 tests per month, enhancing operational capacity and reducing turnaround times for North American samples. This expansion is bolstered by a distribution agreement with Stayhealthy, expected to drive growth across North America. GeneType's tests, which are non-invasive and saliva-based, cover risks for nine diseases, including metabolic, cardiovascular, and oncological conditions. The collaboration aims to meet rising demand for personalized health information.
Genetic Technologies (GTG) and Stayhealthy have announced a distribution agreement to expand the reach of GTG's Multi-Risk Test throughout North America. The Multi-Risk Test will be available via StayHealthyRx, Stayhealthy's online pharmacy platform, which boasts 1.5 million users and comprehensive email outreach capabilities. This collaboration aims to empower individuals with personalized health risk assessments and actionable insights to improve their health. Both companies highlight the synergy between GTG's genetic testing expertise and Stayhealthy's technology-driven health solutions.
Genetic Technologies (ASX: GTG; NASDAQ: GENE) unveiled its innovative geneType Comprehensive Risk Assessment test, targeting 100% of women at risk of breast and ovarian cancer. This test, launched at the 'Know Your Risk' event in California, evaluates both hereditary and sporadic cancer risks for women over 30. The event, co-hosted by Dr. Kristi Funk and Krystal Barter, emphasized genomics' role in women's health. The geneType test represents a significant advancement in preventative healthcare, covering 1 in 8 women in the US at risk for breast cancer (310,000 annual diagnoses) and 19,600 ovarian cancer cases yearly. GTG's new high-throughput automated lab in the US can handle up to 100,000 tests per month, anticipating high demand.
GeneType and Humanise Health hosted the 'Know Your Risk' event on May 23, 2024, in Pasadena, California. This landmark event aimed to empower women through knowledge on genetic testing and risk assessment. Co-hosted by Dr. Kristi Funk and Krystal Barter, the event featured notable panelists who discussed the role of genomics in women's health. Key sessions included discussions on the gender health gap and patient advocacy. A major highlight was the launch of the GeneType hereditary breast and ovarian cancer test, which identifies all women at risk, including those with common gene mutations, regardless of family history. The event aimed to inspire proactive health advocacy among women.
Genetic Technologies (GTG) signed a strategic joint sales & marketing agreement with Wellworks for You Inc. to incorporate geneType tests into its employee wellness solutions, potentially generating 40,000 unit sales in year one. The partnership aims to provide geneType Risk Assessment Testing to Wellworks' 750 employer groups and 2 million covered lives, marking a pivotal milestone for both companies.
Genetic Technologies (GENE) released its Appendix 4C & Quarterly Business Update for Q3 FY24, showcasing key highlights such as cash receipts totaling A$1.8m, a significant increase in geneType adoption, launch of a Comprehensive Risk Assessment Test, and successful fund raising initiatives. The Company also reported on a successful DTC digital media sales campaign in the US and the establishment of a GeneType pilot study in US Breast Screen Imaging Centres.
FAQ
What is the current stock price of Genetic Technologies Ltd. (GENE)?
What is the market cap of Genetic Technologies Ltd. (GENE)?
What is Genetic Technologies Ltd. known for?
What are the main services offered by Genetic Technologies Ltd.?
Where does Genetic Technologies Ltd. generate most of its revenue?
What is BREVAGenplus?
Who primarily uses BREVAGenplus?
What are the company's main operating segments?
What recent milestones has Genetic Technologies Ltd. achieved?
Who can I contact for more information about Genetic Technologies Ltd.?
What is the focus of Genetic Technologies Ltd.'s research?